NeurAxis, Inc. (NRXS)
- GlobeNewswire
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota. The BCBS licensee is the largest pr
- Insider Monkey
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript April 9, 2024 NeurAxis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by and welcome to NeurAxis Fourth Quarter and Fiscal Year 2023 Earnings Conference Call. At […]
- GlobeNewswire
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023. Recent Operational Highlights Expanded total covered lives to approximately 16 million individuals, an increase of 300% compared to 4 milli
